NAVANE (thiothixene hydrochloride) by Pfizer is actions thiothixene is an antipsychotic of the thioxanthene series. First approved in 1971.
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
NAVANE (thiothixene hydrochloride) is an injectable antipsychotic of the thioxanthene class approved in 1971 for treating psychotic disorders. It works through dopamine antagonism, with a chemical and pharmacological profile distinct from phenothiazine antipsychotics. The drug is administered via injection and targets patients with schizophrenia and other psychotic conditions.
As LOE approaches, the brand team is likely smaller and focused on defending market share against generic competition with competitive pressure at 30/100.
ACTIONS Thiothixene is an antipsychotic of the thioxanthene series. Thiothixene possesses certain chemical and pharmacological similarities to the piperazine phenothiazines and differences from the aliphatic group of phenothiazines.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on NAVANE offers limited growth trajectory as the product approaches/is in LOE, with career value centered on defending market share, managing generics, and operational efficiency. This role suits professionals seeking stability in a mature product environment rather than launch excitement or pipeline innovation.
Worked on NAVANE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.